Antithrombotic therapy for prevention of recurrent stroke in the new millenium

References

• Fuster V, Ryden LE, Asinger RVV et al ACC/AHVESC guidelines for the management of patients with atrial fibrillation. jAm. Coll Camila" 38, 1231–1266 (2000).
   Google Scholar
• Hart RG, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation. Ann. Intern. Med. 131,492–501 (1999).
   Google Scholar
• Hart RG. Atrial fibrillation and stroke: concepts and controversies. Stroke 32, 803–808 (2001).
   PubMed Web of Science ®Google Scholar
• Hylek EM, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Eng" Med 335(8), 540–546 (1996).
   Google Scholar
• Hart RG, Rothbart RM, McAnulty JH, Asinger RVV, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J. Am. Coll Camila" 35,183–187 (2000).
   Google Scholar
• Smith NL, Furberg CD, White R, Lima JA, Newman AB, Manolio TA. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch. Intern. Med. 159,1574–1578 (1999).
   PubMedGoogle Scholar
• Waldo AL. Stroke prevention in atrial fibrillation. JAIVIA 290(8), 1093–1095 (2003).
   PubMed Web of Science ®Google Scholar
• Pullicino PM, Thompson JLP Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 54, 288–294 (2000).
   PubMed Web of Science ®Google Scholar
• Graham SR To anticoagulate or not anticoagulate patients with cardiomyopathy. Cardiology Clin. 19(4), 605–615 (2001).
   Google Scholar
• SPIRIT. A randomized trial of anticagulants versus aspirin after cerebral ischaemia of presumed arterial origin. Ann. Neural 42,857–865 (1997).
   PubMed Web of Science ®Google Scholar
• Mohr JP, Lazar RM, Warfarin-Asprin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Eng. Med. 345,1444–1451 (2001).
   Google Scholar
• Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291(5), 576–584 (2004).
   Google Scholar
• Homma S, Sacco RL, Di Tullio MR et al. for the PFO in Cryptogenic Stroke Study (PICSS) Investigators, Effect of medical treatment in stroke patients with patent foramen ovale. Circulation 105(22), 2625–2631 (2002).
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial: is warfarin really a reasonable alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke. Stroke 33,1723 (2002).
   PubMed Web of Science ®Google Scholar
• De Schryver EL. Design of ESPRIT an international randomized trial for secondary prevention after nondisabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Cerebmvasc. Dis.10(2), 147–150 (2000).
   Google Scholar
• Benesch CG. Best treatment for intracranial arterial stenosis? 50 years of uncertainty. The WASID Investigators. Neurology 55 (4), 465–466 (2000) .
   Google Scholar
• Chimowitz MI. Abstract presented at the 29th International Stroke Conference. February 2004. Stroke (2004) (In Press).
   Google Scholar
• Haas WK, Easton JD, Adams HP Jr et al A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Study Group. N Engl J. Med. 321,501–507 (1989).
   PubMed Web of Science ®Google Scholar
• Caprie SC. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348,1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Richardson 12 Kel y M et al. for the African American Antiplatelet Stroke Prevention Study Investigators. Asprin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 289 (22), 2947–2957 (2003).
   Google Scholar
• Yusuf S, Zhao E 11/khta SR et al, for the CURE investigators, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl. J. Med. 345,494-502 (2001).
   Google Scholar
• Steinhubl SR, Berger PB, Mann JTIII et al. for the CREDO Investigators, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Hacke W From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc. Dis. 13\(Suppl. 1), 22–26 (2002).
   Google Scholar
• Benavente O. Antithrombotic therapy in small subcortical strokes. Adv. Neural. 92, 275–280 (2003).
   PubMedGoogle Scholar
• Diener HC, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neural. Sci. 143,1-13 (1996).
   Google Scholar
• Sacco RL, Yusuf S. Prevention Regimen for Effectively avoiding Second Strokes (PROFESS). 29th International Stroke Conference, February 5–7. Stroke 18 (2004).
   Google Scholar
• Zhao L, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br. Pharmacol 134(2), 353–358 (2001).
   PubMed Web of Science ®Google Scholar
• Halperin JL. Stroke prevention using the direct oral thrombin inhibitor ximelagatran in patients with nonvovular atrial fibrillation. 52nd Annual Scientific Session of the American College of Cardiology. J. Am. Coll. Cordial (2003).
   Google Scholar